short bowel syndrome (SBS)

SBS is a complex condition resulting in severe malabsorption of fluids, often requiring costly parenteral nutritional support for survival.

crofelemer’s orphan
drug designation

Crofelemer was granted orphan drug designation for SBS in 2021 by the European Medicines Agency (EMA), and in the US in 2017. Development of crofelemer for the rare disease indications of short bowel syndrome (SBS) and congenital diarrheal disorder (CDD) is the core focus of Napo Therapeutics, an Italian corporation established by Jaguar Health (Napo Pharmaceuticals’ parent company) in 2021 and led by a dedicated team of professionals with rare-disease management experience.

Reference: 1. Schalamon J, Mayr JM, Höllwarth ME. Mortality and economics in short bowel syndrome. Best Pract Res Clin Gastroenterol. 2003;17(6):931-942. doi:10.1016/s1521-6918(03)00079-9